Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CHARLESTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET).
查尔斯敦，马萨诸塞州，2025年1月8日（环球新闻通讯社）-- Solid Biosciences Inc.（纳斯达克：SLDB）（"公司"或"Solid"），一家为神经肌肉和心脏疾病开发精准基因药物的生命科学公司，今天宣布总裁兼首席执行官Bo Cumbo将在2025年1月15日（星期三）下午3:45（太平洋时间）/ 下午6:45（东部时间）在第43届J.P. 摩根医疗会议上进行演讲。
A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.
演讲的现场直播将在公司网站投资者部分的活动页面上提供，或者点击这里。网络直播回放将在活动页面上存档30天。
Institutional investors interested in meeting with management during the conference may reach out to their J.P. Morgan representatives.
有兴趣在会议期间与管理层会面的机构投资者可以与他们的J.P.摩根代表联系。
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid's mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit .
关于Solid Biosciences
Solid Biosciences是一家专注于推进基因治疗候选药物组合的精准基因医学公司，包括用于治疗杜氏肌营养不良症（Duchenne）的SGt-003、用于治疗弗里德里希共济失调的SGt-212、用于治疗儿茶酚胺多形性室性心动过速（CPVT）的SGt-501、用于治疗TNNT2介导的扩张型心肌病的SGt-601、用于治疗BAG3介导的扩张型心肌病的SGt-401，以及用于治疗致命性心脏疾病的其他资产。Solid正在推进其在罕见神经肌肉和心脏疾病方面的多样化管线，汇集了科学、技术、疾病管理和护理的专家。以患者为中心，由那些直接受影响的人创立，Solid的任务是改善生活在这些毁灭性疾病中的患者的日常生活。有关更多信息，请访问。
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Solid Biosciences 投资者联系：
妮可·安德森
董事，投资者关系与企业通信
Solid Biosciences 公司
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
媒体联系人：
格伦·白银
FINN Partners
glenn.silver@finnpartners.com
